A novel potent, oral potassium-competitive acid blocker (P-CAB) that potently inhibits H+,K+-ATPase with IC50 of 19 nM; completely inhibits basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats (4mg/kg, p.o.); increases the pH of gastric perfusate to a higher value, and sustains longer than those of lansoprazole or SCH28080; a clinical candidate for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer, and other acid-related diseases.
